ArticleDiscover oncology2025
DNA methylation expression patterns predict outcome of clear cell renal cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identifying pleiotropic genes for backfat thickness and semen traits in pigs using GWAS summary data.Journal of animal science · 2026Article
- Promoter Hypermethylation-Driven NPHS2 Silencing Promotes Immune Escape and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.Oncology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo identify DNA methylation markers related to clear cell renal cell carcinoma (ccRCC) prognosis and construct a prognostic model.
methodsMethylation data from TCGA and GSE113501 dataset were analyzed. Differential analysis, univariate Cox regression, and LASSO regression were used to find survival-related CpG sites and build a risk score model. The model was evaluated by the area under the curve, and multivariate analysis determined risk factors.
resultsWe determined 13 CpGs that are significantly associated with prognosis through a series of regression analyses and established a risk model based on them. Patients were divided into a high-risk group and a low-risk group according to the median risk score. The results showed that there was a significant difference in the overall survival rate between the two groups (p < 0.001), and the area under the curve (AUC) of the model was greater than 0.8. Verified by the GSE113501 dataset, the model performed well in distinguishing ccRCC with different progression states. In addition, by combining methylation data with gene expression analysis, five methylation-related differentially expressed genes (LINC02541, SLAMF8, LPXN, LGALS12, EGFR) were identified, and their expression levels were significantly upregulated in tumor tissues. Multivariate analysis indicated that age, clinical stage, and methylation risk score were independent prognostic factors.
conclusionThis study confirmed that DNA methylation markers can effectively predict the progression and prognosis of clear cell renal cell carcinoma (ccRCC), providing a highly efficient and minimally invasive assessment tool for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.